Derma Sciences (DSCI) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 11, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'DERMA SCIENCES, INC.	'
Entity Central Index Key	'0000892160	'
Trading Symbol	'DSCI	'
Amendment Flag	'false	'
Document Type	'10-Q	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'
Document Period End Date	30-Sep-13	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	17,285,084

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$5,393,788	$41,616,657
Short-term investments	20,726,000	3,730,000
Accounts receivable, net	8,510,456	7,085,713
Inventories	15,087,585	13,670,588
Prepaid expenses and other current assets	3,342,859	3,209,031
Total current assets	53,060,688	69,311,989
Long-term investments	9,186,931	498,000
Equipment and improvements, net	3,033,174	3,304,852
Identifiable intangible assets, net	15,084,600	17,128,883
Goodwill	13,457,693	13,457,693
Other assets	140,303	141,213
Total Assets	93,963,389	103,842,630
Current Liabilities	'	'
Accounts payable	5,338,091	3,993,687
Accrued expenses and other current liabilities	4,226,018	4,132,934
Total current liabilities	9,564,109	8,126,621
Long-term liabilities	262,584	268,517
Deferred tax liability	1,678,060	1,736,299
Total Liabilities	11,504,753	10,131,437
Stockholders' Equity	'	'
Convertible preferred stock, $.01 par value; shares authorized 1,468,750; issued and outstanding 73,332 at September 30, 2013 and December 31, 2012 (liquidation preference of $3,222,368 at September 30, 2013)	733	733
Common stock, $.01 par value; shares authorized 35,000,000; issued and outstanding 17,268,486 at September 30, 2013 and 16,524,723 at December 31, 2012	172,685	165,247
Additional paid-in capital	139,051,638	132,163,083
Accumulated other comprehensive income	1,978,560	1,588,888
Accumulated deficit	-58,744,980	-40,206,758
Total Stockholders' Equity	82,458,636	93,711,193
Total Liabilities and Stockholders' Equity	$93,963,389	$103,842,630

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Consolidated Balance Sheets [Abstract]	'	'
Convertible preferred stock, par value per share	$0.01	$0.01
Convertible preferred stock, shares authorized	1,468,750	1,468,750
Convertible preferred stock, shares issued	73,332	73,332
Convertible preferred stock, shares outstanding	73,332	73,332
Convertible preferred stock, liquidation preference	$3,222,368	'
Common stock, par value per share	$0.01	$0.01
Common stock, shares authorized	35,000,000	25,000,000
Common stock, shares issued	17,268,486	16,524,723
Common stock, shares outstanding	17,268,486	16,524,723

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements of Comprehensive Loss [Abstract]	'	'	'	'
Net Sales	$22,080,434	$19,649,773	$59,018,241	$52,536,938
Cost of sales	14,046,660	12,741,599	37,605,841	34,554,029
Gross Profit	8,033,774	6,908,174	21,412,400	17,982,909
Operating Expenses	'	'	'	'
Selling, general and administrative	10,743,489	8,058,441	31,419,944	23,646,715
Research and development	2,677,539	1,923,670	8,913,303	4,553,697
Total operating expenses	13,421,028	9,982,111	40,333,247	28,200,412
Operating loss	-5,387,254	-3,073,937	-18,920,847	-10,217,503
Other income, net:	'	'	'	'
Interest income	-16,510	-2,454	-30,561	-13,304
Other income, net	-144,226	-66,781	-58,102	-65,596
Total other income, net	-160,736	-69,235	-88,663	-78,900
Loss before income taxes	-5,226,518	-3,004,702	-18,832,184	-10,138,603
Income tax (benefit) provision	-277,755	50,304	-293,969	-1,752,647
Net Loss	-4,948,763	-3,055,006	-18,538,215	-8,385,956
Other Comprehensive Income (Loss)	'	'	'	'
Foreign currency translation adjustment	29,061	156,283	-190,039	149,113
Unrealized gain on equity securities, net of taxes	579,711	'	579,711	'
Total other comprehensive income	608,772	156,283	389,672	149,113
Comprehensive Loss	($4,339,991)	($2,898,723)	($18,148,543)	($8,236,843)
Net loss per common share - basic and diluted	($0.29)	($0.24)	($1.09)	($0.69)
Shares used in computing net loss per common share - basic and diluted	17,262,688	12,875,476	16,977,524	12,068,520

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating Activities	'	'
Net loss	($18,538,215)	($8,385,956)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of equipment and improvements	689,948	771,402
Amortization of intangible assets	2,144,283	1,177,804
Provision for bad debts	21,000	8,080
Allowance for sales adjustments	18,122	35,610
Provision for inventory obsolescence	109,862	171,595
Loss on disposal of equipment	'	25,885
Deferred rent expense	1,019	740
Stock based compensation	4,161,221	1,670,288
Deferred income taxes	-234,934	-1,799,970
Changes in operating assets and liabilities:	'	'
Accounts receivable	-1,458,367	-103,287
Inventories	-1,694,372	-3,847,932
Prepaid expenses and other current assets	-279,008	289,395
Other assets	-26,094	-3,735
Accounts payable	1,368,750	367,390
Accrued expenses and other current liabilities	127,149	195,562
Net cash used in operating activities	-13,589,636	-9,427,129
Investing Activities	'	'
Investment in acquired business, net of cash acquired	'	-14,357,578
Purchase of investments	-33,723,000	-4,976,000
Proceeds from sale of investments	8,980,000	5,725,000
Purchase of equipment and improvements	-503,652	-610,246
Proceeds from sale of equipment	'	43,000
Purchase of identifiable intangible assets	-100,000	-1,300,000
Net cash used in investing activiites	-25,346,652	-15,475,824
Financing Activities	'	'
Proceeds from the sale of common stock, net of costs	'	17,799,874
Proceeds from exercise of stock options and warrants, net of costs	2,811,218	963,759
Payment of withholding taxes related to employee stock compensation	-76,446	-76,039
Net cash provided by financing activities	2,734,772	18,687,594
Effect of exchange rate changes on cash and cash equivalents	-21,353	243
Net decrease in cash and cash equivalents	-36,222,869	-6,215,116
Cash and cash equivalents	'	'
Beginning of period	41,616,657	17,110,350
End of period	5,393,788	10,895,234
Supplemental disclosures of cash flow information:	'	'
Cash paid during the year for interest	$719	$1,724

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Organization and Summary of Significant Accounting Policies [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	1	Organization and Summary of Significant Accounting Policies
	Derma Sciences, Inc. and its subsidiaries (the "Company") is a medical technology company focused on three segments of the wound care marketplace: advanced wound care, traditional wound care and pharmaceutical wound care products. The Company has one drug candidate that initiated its Phase 3 study during the first quarter of 2013. The Company markets its products principally through direct sales representatives in the United States ("U.S."), Canada and the United Kingdom ("U.K."), and through independent distributors within other select international markets. The Company's U.S. distribution facilities are located in St. Louis, Missouri and Houston, Texas. The Company utilizes third party distributors for distribution in Canada, Europe and the Far East. The Company also has manufacturing facilities in Toronto, Canada and Nantong, China.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013, are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. Information included in the consolidated balance sheet as of December 31, 2012 has been derived from the consolidated financial statements and footnotes thereto for the year ended December 31, 2012, included in the Annual Report on Form 10-K previously filed with the Securities and Exchange Commission. For further information refer to the Annual Report on Form 10-K.
	Principles of Consolidation - The consolidated financial statements include the accounts of Derma Sciences, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates - The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on knowledge of current events and actions which may be undertaken in the future, actual results may ultimately differ from these estimates. Estimates and assumptions are required in the determination of sales deductions for trade rebates, sales incentives, discounts and allowances. Significant estimates and assumptions are also required in determining the appropriateness of amortization periods for identifiable intangible assets, the potential impairment of goodwill and the valuation of inventory.
	Revenue Recognition - Sales are recorded when product is shipped or title passes to customers and collectability is reasonably assured. Gross sales are adjusted for cash discounts, returns and allowances, trade rebates, distribution fees (in Canada) and other sales deductions in the same period that the related sales are recorded. Freight costs billed to and reimbursed by customers are recorded as a component of revenue. Freight costs to ship product to customers are recorded as a component of cost of sales.
	Net Loss per Share - Net loss per common share - basic is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Net loss per common share - diluted reflects the potential dilution of earnings by including the effects of the assumed exercise, conversion or issuance of potentially issuable shares of common stock ("potentially dilutive securities"), including those attributable to stock options, warrants, convertible preferred stock and restricted stock units in the weighted average number of common shares outstanding for a period, if dilutive. The effects of the assumed exercise of warrants and stock options are determined using the treasury stock method. Potentially dilutive securities have not been included in the computation of diluted loss per share for the three and nine months ended September 30, 2013 and 2012 as the effect would be anti-dilutive.
	Potentially dilutive shares excluded as a result of the effects being anti-dilutive are as follows:
			Three and Nine Months Ended
			September 30,
			2013		2012
	Dilutive shares:
	Convertible preferred stock			73,332		73,332
	Additional stock issuable related to conversion of preferred stock			59,154		-
	Restricted share units			802,800		52,900
	Warrants			2,305,272		2,951,404
	Stock options			1,832,581		1,704,110
	Total dilutive shares			5,073,139		4,781,746

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2013
Acquisition [Abstract]	'
Acquisition	'
		2	Acquisition
	On April 16, 2012, the Company acquired all of the outstanding stock of MedEfficiency, Inc. ("MedEfficiency") pursuant to the terms of an Agreement and Plan of Merger. The purchase price was $14,475,000 and was funded by the Company with cash on hand.
	MedEfficiency develops, manufactures and markets medical devices for treating chronic wounds and lower extremity injuries, specializing in total contact casting ("TCC") products. The TCC-EZ total contact cast system is MedEfficiency's lead product, in addition to a line of traditional and specialized contact casts and related equipment. The Company has distributed MedEfficiency's TCC products since 2008 under an exclusive distribution agreement.
	The acquisition has been accounted for as a purchase. Accordingly, the results of operations of MedEfficiency have been included in the consolidated financial statements commencing April 17, 2012. The allocation of the purchase price to the estimated fair value of the assets acquired and the liabilities assumed is outlined below:
	Current assets		$	925,817
	Equipment			29,579
	Acquired intangible assets			10,700,000
	Goodwill			6,337,967
	Total assets acquired			17,993,363
	Current liabilities			653,315
	Deferred tax liability			2,982,470
	Total liabilities assumed			3,635,785
	Net assets acquired		$	14,357,578
	Purchase price		$	14,475,000
	Less cash acquired			117,422
	Net cash paid		$	14,357,578
	The allocation of the purchase price to the assets acquired and liabilities assumed was based on an independent valuation study to establish the fair value of the identifiable intangible assets acquired. The identifiable intangible assets acquired consist of developed technology and patents, customer relationships, a supply agreement, trade names and trademarks and non-compete agreements. The Company recorded the excess of the purchase price over the fair values of the identifiable assets acquired and liabilities assumed as goodwill. While the acquired intangible assets are amortizable for financial reporting purposes, the acquired intangible assets and goodwill are not deductible for tax purposes. Deferred taxes have been recorded associated with the acquisition for the basis differences for financial reporting and income tax purposes for the acquired identifiable intangible assets at the effective tax rates for the period in which the deferred tax asset and liability are expected to reverse.
	The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of April 16, 2012. The pro forma information is based on historical results adjusted for the effect of purchase accounting and is not necessarily indicative of the results of operations of the combined entity had the acquisition occurred at the beginning of the periods presented, nor is it necessarily indicative of future results.
			Nine months ended,
			30-Sep-12
			(Unaudited)
	Net Sales		$	53,924,427
	Net Loss		$	(8,898,587	)
	Net Loss per common share:
	Basic and Diluted		$	(0.74	)
	Weighted average number of shares:
	Basic and Diluted			12,068,520
	The proforma results of operations for the nine months ended September 30, 2013 include a deferred income tax benefit of $1,934,153 associated with the acquisition for differences in financial and income tax reporting basis differences of the acquired identifiable intangible assets at the effective tax rates for the period in which the deferred tax assets and liabilities are expected to reverse.

Cash_and_Cash_Equivalents_and_

Cash and Cash Equivalents and Investments	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents and Investments [Abstract]	'
Cash and Cash Equivalents and Investments	'
	3	Cash and Cash Equivalents and Investments
	Cash and Cash Equivalents
	The Company considers cash and cash equivalents as amounts on hand, on deposit in financial institutions and highly liquid investments purchased with an original maturity of three months or less. The Company maintains cash with various domestic and foreign financial institutions within the ordinary course of business, which at times may exceed jurisdictional insurance limits. Money market mutual funds consist of funds deposited into mutual funds investing in U.S. government obligations that are fully secured by the U.S. government.
	Investments
	Investments in debt securities include certificates of deposit purchased with an original maturity greater than three months which are deposited in various U.S. financial institutions and are fully insured by the Federal Deposit Insurance Corporation. The Company intends to hold the certificate of deposits to maturity and accordingly these investments are carried at cost. Investment in equity securities include shares of Comvita Limited stock (see note 9) which are classified as an available for sale investment carried at fair value, and any unrealized gains and losses associated with the investment are included in accumulated other comprehensive income. Investment in debt securities with maturities greater than one year from the balance sheet date and the investment in shares of Comvita Limited stock are classified as a long-term asset.
	Cash and cash equivalents and investments at September 30, 2013 and December 31, 2012 consisted of the following:
			September 30,		December 31,
			2013		2012
	Cash		$	3,939,203	$	4,909,663
	Money market mutual funds			1,454,585		36,706,994
	Cash and cash equivalents			5,393,788		41,616,657
	Investments in debt securities			21,971,000		4,228,000
	Investment in equity securities			7,941,931		-
	Total Investments			29,912,931		4,228,000
	Total cash and cash equivalents and investments		$	35,306,719	$	45,844,657
	The following table provides fair value information as of September 30, 2013:
					Fair Value Measurements, Using
			Total carrying		Quoted prices		Significant other		Significant
			value as of		in active		observable		unobservable
			September 30,		markets		inputs		inputs
			2013		(Level 1)		(Level 2)		(Level 3)
	Cash and cash equivalents		$	5,393,788	$	5,393,788	$	-	$	-
	Investments in debt securities			21,971,000		21,959,311		-		-
	Investment in equity securities			7,941,931		7,941,931		-		-
	Total Investments			29,912,931		29,901,242		-		-
	Total		$	35,306,719	$	35,295,030	$	-	$	-
	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets. Level 2 inputs are quoted prices for similar assets in active markets or inputs that are observable for the asset, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management's own assumptions used to measure assets at fair value. A financial asset's classification is determined based on the lowest level input that is significant to the fair value measurement.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventories [Abstract]	'
Inventories	'
		September 30,		December 31,
		2013		2012
	Finished goods	$	10,037,372	$	9,574,685
	Work in process		889,754		554,129
	Packaging materials		1,139,886		991,157
	Raw materials		3,020,573		2,550,617
	Total inventory	$	15,087,585	$	13,670,588

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	5	Stockholders' Equity
	Preferred Stock
	Subsequent to the issuances of the preferred stock, the Company has undertaken a number of common stock offerings that would impact the preferred stock conversion ratios. Previous preferred stockholders who have converted their preferred shares will receive an additional 141,448 shares of common stock as a result of the conversion ratio adjustments, of which 130,051 shares were issued during the nine months ended September 30, 2013 and 11,397 remain issuable. As of September 30, 2013, current Series A and B preferred stockholders holding 73,332 preferred shares are entitled to receive an aggregate of 121,089 shares of common stock upon conversion of their holdings, as a result of the conversion ratio adjustments. The number of shares issuable upon conversion is subject to further adjustment should the Company in the future undertake one or more offerings of its common stock at less than the prevailing market price.
	The 141,448 incremental shares associated with the conversion ratio adjustment will be recorded to common stock at par with the offset to additional paid in capital when issued as all of the convertible preferred stock was issued prior to the November 16, 2000 effective date of certain provisions of ASC 470 (formerly, EITF 00-27 Application of Issue No. 98-5 to Certain Convertible Instruments).
	Common Stock
	On May 22, 2013, shareholders of the Company approved the proposal to increase the number of authorized shares of common stock from 25,000,000 to 35,000,000. During the nine months ended September 30, 2013, the Company issued 743,763 shares of common stock consisting of: 550,292 shares upon the exercise of stock purchase warrants and options for which the Company received $2,811,218 (net of $28,208 in expenses), 130,051 shares in connection with the preferred stock ratio adjustments, 58,970 shares in connection with the vesting of 66,900 shares of restricted common stock net of the shares withheld for payment of withholding taxes, and 4,450 shares to a retired director of the Company for consulting services.
	Stock Purchase Warrants
	At September 30, 2013, the Company had warrants outstanding to purchase shares of the Company's common stock consisting of the following:
	Series		Number of Warrants			Exercise Price			Expiration Date
	L			6,250		$	3.12		31-Mar-14
	N			100,000		$	6.25		22-Feb-15
	O			230,900		$	5.5		22-Feb-15
	P			2,187		$	6.25		16-Feb-15
	Q			133,333		$	5.5		22-Feb-15
	R			1,832,602		$	9.9		22-Jun-16
	Total			2,305,272
	During the nine months ended September 30, 2013, a total of 624,882 warrants were exercised on a for cash and cashless basis consisting of 367,814 Series K, 200,893 Series J, 53,667 Series O, and 2,508 Series P warrants. A total of 421,465 shares of common stock were issued in connection with the 2013 warrant exercises.
	Equity Based Compensation
	Under the Equity Incentive Plan (the "EIP Plan") the Company is authorized to issue shares of common stock. On May 22, 2013, shareholders of the Company approved the proposal to increase the number of authorized shares of common stock the Company can issue from 2,812,500 to 4,500,000. The EIP Plan authorizes the Company to grant equity-based and cash-based incentive compensation in the form of stock options, stock appreciation rights, restricted shares, restricted share units, other share-based awards and cash-based awards, for the purpose of providing the Company's employees, non-employee directors and consultants with incentives and rewards for performance. At September 30, 2013, options to purchase 1,832,581 shares and 802,800 restricted share units were issued and outstanding under the EIP Plan and 1,436,849 shares were available for grant.
	Stock Options
	The EIP Plan permits the granting of both incentive and nonqualified stock options to employees and nonqualified stock options to non-employee directors and consultants of the Company. The option exercise price may not be less than the fair market value of the stock on the date of the grant of the option. The duration of each option may not exceed 10 years from the date of grant.
	For the three and nine months ended September 30, 2013 and 2012, the fair value of each option award was estimated at the date of grant using the Black-Scholes option pricing model. The weighted-average assumptions used were as follows:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Risk-free interest rate			2	%		0.9	%		1.26	%		1.12	%
	Volatility factor			67.9	%		72.2	%		69.9	%		74.4	%
	Dividend yield			0	%		0	%		0	%		0	%
	Expected option life (years)			6.25			6.25			6.25			6.25
	The risk-free rate utilized represents the U.S. treasury yield curve rate for the expected option life at the time of grant. The volatility factor was calculated based on the Company's historical stock price volatility equal to the expected life of the option at the grant date. The dividend yield is 0% since the Company does not anticipate paying dividends in the near future. The simplified expected option life method is used to determine the 6.25 year expected option life for Company employees and directors while the 10 year contractual option life period is utilized for consultants.
	Based on the Company's historical experience of options that were forfeited before becoming fully vested, the Company has assumed an annualized forfeiture rate of 1.0% for all options. The Company will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated.
	A summary of the Company's stock option activity and related information for the nine months ended September 30, 2013 was as follows:
			Options			Weighted
						Average
						Exercise Price
	Outstanding - January 1, 2013			1,639,985		$	6.38
	Granted			414,230		$	12.15
	Exercised			(178,261	)	$	5.58
	Forfeited			(19,918	)	$	9.94
	Expired			(23,455	)	$	13.47
	Outstanding - September 30, 2013			1,832,581		$	7.69
	Expected to vest - September 30, 2013			1,814,255		$	7.69
	Exercisable at September 30, 2013			1,335,542		$	6.46
	During 2013, the Company granted 288,630 service based options and 125,600 performance based options to Company employees and consultants. The weighted average fair value per share of options granted during the nine months ended September 30, 2013 was $8.29.
	During the nine months ended September 30, 2013, 178,261 stock options were exercised on a for cash and cashless basis. A total of 128,827 shares of common stock were issued in connection with the 2013 stock option exercises. The intrinsic value of options exercised in 2013 was $1,229,992.
	During the three and nine months ended September 30, 2013 and 2012, stock option compensation expense was recorded as follows:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Cost of sales		$	17,337		$	9,362		$	85,678		$	30,427
	Selling, general and administrative expenses			536,755			286,402			1,672,548			1,301,442
	Research and development			55,925			13,913			127,580			31,162
	Total stock option compensation expense		$	610,017		$	309,677		$	1,885,806		$	1,363,031
	As of September 30, 2013, there was $1,960,427 of unrecognized compensation cost related to nonvested service based awards and $320,857 related to nonvested performance based awards. These costs are expected to be recognized over the options' remaining weighted average vesting period of 1.85 years for the service and 0.25 years for the performance based awards.
	Restricted Share Units
	The Company has issued service, performance and market based restricted share units to employees and directors of the Company. Expense for restricted share awards is amortized on a straight-line basis over the awards' vesting period. The fair value of service and performance awards are determined using the quoted market price of the Company's common stock on the date of grant, while market based performance awards are valued using a binomial/lattice pricing model.
	The following table summarizes the restricted share unit activity for the period:
			Number			Weighted
			of Shares			Average Fair Value
	Unvested January, 1, 2013			786,900		$	7.07
	Granted			82,800			13.66
	Vested			(66,900	)		9.52
	Unvested, September 30, 2013			802,800		$	9.22
In connection with the vesting of restricted share unit awards during the nine months ended September 30, 2013, 7,930 common stock shares with a fair value of $76,446 were withheld in satisfaction of employee tax withholding obligations.
During the three months ended September 30, 2013 and 2012, restricted share unit compensation expense was $745,067 and $109,289 and for the nine months ended September 30, 2013 and 2012 was $1,937,993 and $307,257 respectively and included in selling, general and administrative expense.
As of September 30, 2013, there was $5,449,413 of unrecognized compensation cost related to unvested restricted share units. These costs are expected to be recognized over the restricted shares units' remaining weighted average vesting period of 2.43 years.
In consideration of prior service to the Company, a retiring director received 5,000 restricted share units, acceleration of the vesting of any unvested stock options and restricted share units and extension of the date to exercise vested stock options to the earlier of 36 months or the awards original expiration date (versus 90 days) from the date of the retirement. Also during the nine months ended September 30, 2013, the Company granted 4,450 shares of common stock to a former director for consulting services. An additional $337,422 of stock based compensation expense was recognized during the nine months ended September 30, 2013 and included in selling, general and administrative expense in connection with these activities.
Shares Reserved for Future Issuance
At September 30, 2013, the Company had reserved the following shares of common stock for future issuance:
Convertible preferred shares (series A - B)			73,332
Additional stock issuable related to conversion of preferred stock			59,154
Common stock options outstanding			1,832,581
Common stock warrants outstanding			2,305,272
Restricted share units outstanding			802,800
Common stock equivalents available for grant			1,436,849
Total common stock shares reserved			6,509,988

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Accumulated Other Comprehensive Income	'
		6	Accumulated Other Comprehensive Income
			The Company's accumulated other comprehensive income as of September 30, 2013 was as follows:
			Foreign Currency			Unrealized Gain on		Total
			Translation			Equity Securities,
			Adjustments			Net of Taxes
	Balance at January 1, 2013		$	1,588,888		$	-	$	1,588,888
	Current period - other comprehensive income (loss)			(190,039	)		579,711		389,672
	Balance at September 30, 2013		$	1,398,849		$	579,711	$	1,978,560

Operating_Segments

Operating Segments	9 Months Ended
	Sep. 30, 2013
Operating Segments [Abstract]	'
Operating Segments	'
	7	Operating Segments
	The Company operates in three segments: advanced wound care, traditional wound care and pharmaceutical wound care products. They are managed separately as each segment requires different technology, marketing and sales strategies. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, bandages and ointments designed to promote wound healing and/or prevent infection. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closer strips, catheter fasteners and skin care products. Pharmaceutical wound care products consist of DSC127, a novel product for the treatment of diabetic foot ulcers which is presently under development.
	Advanced and traditional wound care products are marketed globally to acute care, extended care, home health care, wound and burn care clinics and physician offices. The Company utilizes a broad network of well-established distributors to deploy the majority of its products to end users. A smaller portion of the Company's sales are sold directly to end users. The advanced and traditional wound care products are both manufactured internally and sourced from third party suppliers. The majority of marketing expenses are deployed in support of advanced wound care products with traditional wound care products requiring limited support. The Company utilizes direct sales representatives, distributor relationships and contractual relationships with buying groups and wound care service providers to sell its products. Direct sales representatives are used solely in support of advanced wound care sales in the U.S. and the U.K. and for both advanced and traditional wound care products in Canada.
	The pharmaceutical wound care segment is presently limited to the development of DSC127.
	Each operating segment is managed at the segment contribution level consisting of gross profit minus direct expense consisting of distribution, marketing, sales, research and development and intangible amortization expenses. Expenses are allocated directly by segment to the extent possible. Expenses common to all three operating segments are allocated consistently using activity based assumptions. The aggregation or allocation of indirect expenses by segment is not practical.
	Operating segment sales, gross profit, segment contribution and other related information for 2013 and 2012 were as follows:
	Three Months Ended September 30, 2013
			Advanced			Traditional			Pharmaceutical			Other			Total
			Wound Care			Wound Care			Wound Care						Company
	Net sales		$	9,090,598		$	12,989,836		$	-		$	-		$	22,080,434
	Gross profit			4,524,951			3,508,823			-			-			8,033,774
	Direct expense			(5,451,888	)		(1,367,019	)		(2,704,215	)		-			(9,523,122	)
	Segment contribution		$	(926,937	)	$	2,141,804		$	(2,704,215	)		-			(1,489,348	)
	Indirect expenses											$	(3,459,415	)		(3,459,415	)
	Net loss														$	(4,948,763	)
	Three Months Ended September 30, 2012
	Net sales		$	6,829,168		$	12,820,605		$	-		$	-		$	19,649,773
	Gross profit			3,557,759			3,350,415			-			-			6,908,174
	Direct expense			(4,466,645	)		(1,058,973	)		(1,935,919	)		-			(7,461,537	)
	Segment contribution		$	(908,886	)	$	2,291,442		$	(1,935,919	)		-			(553,363	)
	Indirect expenses											$	(2,501,643	)		(2,501,643	)
	Net loss														$	(3,055,006	)
	Nine Months Ended September 30, 2013
			Advanced			Traditional			Pharmaceutical			Other			Total
			Wound Care			Wound Care			Wound Care						Company
	Net sales		$	24,489,596		$	34,528,645		$	-		$	-		$	59,018,241
	Gross profit			12,080,637			9,331,763			-			-			21,412,400
	Direct expense			(15,883,488	)		(3,847,234	)		(8,989,976	)		-			(28,720,698	)
	Segment contribution		$	(3,802,851	)	$	5,484,529		$	(8,989,976	)		-			(7,308,298	)
	Indirect expenses											$	(11,229,917	)		(11,229,917	)
	Net loss														$	(18,538,215	)
	Nine Months Ended September 30, 2012
	Net sales		$	17,126,374		$	35,410,564		$	-		$	-		$	52,536,938
	Gross profit			8,787,986			9,194,923			-			-			17,982,909
	Direct expense			(12,695,205	)		(3,311,086	)		(4,593,012	)		-			(20,599,303	)
	Segment contribution		$	(3,907,219	)	$	5,883,837		$	(4,593,012	)		-			(2,616,394	)
	Indirect expenses											$	(5,769,562	)		(5,769,562	)
	Net loss														$	(8,385,956	)
	The following table presents net sales by geographic region.
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	United States			77	%		70	%		78	%		70	%
	Canada			13	%		22	%		13	%		21	%
	Other			10	%		8	%		9	%		9	%
	For the nine months ended September 30, 2013 and 2012, the Company had a major Canadian customer comprising 12% and 20%, respectively, of consolidated net sales. Due to outstanding rebate obligations, the Company was in a net liability position to this customer at September 30, 2013.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	8	Income Taxes
	The following table summarizes the income tax expense and effective tax rate for the three and nine months ended September 30, 2013 and 2012:
			Three Months Ended September 30,
			2013			2012
	Current tax expense		$	31,819		$	20,551
	Deferred tax (benefit) expense			(309,574	)		29,753
	Income tax (benefit) expense		$	(277,755	)	$	50,304
	Effective tax rate			5.3	%		(1.7	)%
			Nine Months Ended September 30,
			2013			2012
	Current tax (benefit) expense		$	(59,035	)	$	47,323
	Deferred tax benefit			(234,934	)		(1,799,970	)
	Income tax benefit		$	(293,969	)	$	(1,752,647	)
	Effective tax rate			1.6	%		17.3	%
	The income tax benefit for the three and nine months ended September 30, 2013 consisted of a U.S. deferred income tax benefit related to a reduction in the Company's U.S. valuation allowance to offset the tax impact of the unrealized gain on equity securities included in accumulated other comprehensive income and a foreign tax expense for the three months ended September 30, 2013 and benefit for the nine months ended September 30, 2013 from foreign operations. In addition, the U.S. income tax benefit for the three and nine months ended September 30, 2013 was increased by the tax effect of periodic amortization of nondeductible acquired intangible assets acquired in the MedEfficiency acquisition offset by an expense related to indefinite lived intangible assets.
	The income tax expense (benefit) for 2012 consisted of a U.S. deferred income tax expense related to indefinite lived intangible assets reduced by a deferred income tax benefit from periodic amortization of nondeductible acquired intangible assets.and an income tax expense from foreign operations. The income tax benefit for the nine months ended September 30, 2012 also included a $1,887,383 deferred tax benefit associated with the reduction in the Company's U.S. valuation allowance. This benefit reflected the adjustment to record the deferred tax asset and liability (principally related to the non-deductible intangible assets acquired) associated with the MedEfficiency acquisition at the effective tax rates for the period in which the deferred tax asset and liability are expected to reverse.

Investment_in_Comvita

Investment in Comvita	9 Months Ended
	Sep. 30, 2013
Investment in Comvita [Abstract]	'
Investment in Comvita	'
	9	Investment in Comvita
	In September 2013, the Company purchased 2,272,277 shares of Comvita Limited ("Comvita") common stock for $7,000,000 pursuant to a subscription agreement. The equity investment represents 7.3% of Comvita's outstanding shares. In conjunction with this investment, the Company's chairman and chief executive officer was named to Comvita's board of directors. Comvita will use the proceeds from this investment to purchase additional apiaries and upgrade and expand its Manuka honey processing capabilities. This investment will assist Comvita in its effort to better ensure supply for the Company's medical-grade honey requirements in an environment of growing global demand for Manuka honey.
	As of September 30, 2013, the fair value of the Comvita stock was $7,941,931 as determined by the quoted market price of the outstanding stock on the New Zealand stock exchange. The $941,931 fair value increase, net of taxes of $362,220, was recorded in accumulated other comprehensive income.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	10	Commitments and Contingencies
	New Cast Industry Co., Ltd. Supply Agreement
	On March 27, 2013, the Company entered into a supply agreement (the "International Agreement") with New Cast Industry Co., Ltd. ("NCIC") relating to NCIC's proprietary technology for the casting element within the TCC-EZ total contact casting system (the "Technology"). The Company has been purchasing product from NCIC utilizing the Technology in the TCC-EZ series of total contact casting system products for TCC-EZ product sales within North America pursuant to the supply agreement dated April 17, 2012 (the "North America Agreement"), and intends to continue to do so.
	Under the International Agreement, NCIC agreed to exclusively supply the Company with its product utilizing the Technology and granted the Company the exclusive right to sell products incorporating the Technology outside North America. If the Company does not achieve the first commercial sale of a product incorporating the Technology in Latin America, Europe, Middle East, Australia, Asia and India (the "Territory") by certain dates, NCIC has the right, as its sole remedy, to convert the exclusive license in the Territory to a non-exclusive license. Unless otherwise terminated pursuant to the terms of the International Agreement, the term is for five years with automatic five year renewals.
	In consideration for the exclusive international rights set forth above, the Company paid NCIC $200,000. Provided this agreement has not been terminated as a result of a breach by the Company, NCIC will refund $100,000 to the Company on the first anniversary of the International Agreement. The initial cost of $100,000 has been capitalized as an identifiable intangible asset and is being amortized over the initial five year term of the agreement, and a $100,000 deposit has been recorded. Further, the International Agreement includes milestone payments of up to $1,000,000 to NCIC based upon achievement of international net sales levels during a calendar year.
	Contingencies
	On occasion, the Company is involved in claims and other legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company's consolidated financial position, results of operations, or liquidity.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2013
Organization and Summary of Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013, are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. Information included in the consolidated balance sheet as of December 31, 2012 has been derived from the consolidated financial statements and footnotes thereto for the year ended December 31, 2012, included in the Annual Report on Form 10-K previously filed with the Securities and Exchange Commission. For further information refer to the Annual Report on Form 10-K.
Principles of Consolidation	'
	Principles of Consolidation - The consolidated financial statements include the accounts of Derma Sciences, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates - The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on knowledge of current events and actions which may be undertaken in the future, actual results may ultimately differ from these estimates. Estimates and assumptions are required in the determination of sales deductions for trade rebates, sales incentives, discounts and allowances. Significant estimates and assumptions are also required in determining the appropriateness of amortization periods for identifiable intangible assets, the potential impairment of goodwill and the valuation of inventory.
Revenue Recognition	'
	Revenue Recognition - Sales are recorded when product is shipped or title passes to customers and collectability is reasonably assured. Gross sales are adjusted for cash discounts, returns and allowances, trade rebates, distribution fees (in Canada) and other sales deductions in the same period that the related sales are recorded. Freight costs billed to and reimbursed by customers are recorded as a component of revenue. Freight costs to ship product to customers are recorded as a component of cost of sales.
Net Loss per Share	'
	Net Loss per Share - Net loss per common share - basic is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Net loss per common share - diluted reflects the potential dilution of earnings by including the effects of the assumed exercise, conversion or issuance of potentially issuable shares of common stock ("potentially dilutive securities"), including those attributable to stock options, warrants, convertible preferred stock and restricted stock units in the weighted average number of common shares outstanding for a period, if dilutive. The effects of the assumed exercise of warrants and stock options are determined using the treasury stock method. Potentially dilutive securities have not been included in the computation of diluted loss per share for the three and nine months ended September 30, 2013 and 2012 as the effect would be anti-dilutive.
	Potentially dilutive shares excluded as a result of the effects being anti-dilutive are as follows:
		Three and Nine Months Ended
		September 30,
		2013		2012
	Dilutive shares:
	Convertible preferred stock		73,332		73,332
	Additional stock issuable related to conversion of preferred stock		59,154		-
	Restricted share units		802,800		52,900
	Warrants		2,305,272		2,951,404
	Stock options		1,832,581		1,704,110
	Total dilutive shares		5,073,139		4,781,746

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Organization and Summary of Significant Accounting Policies [Abstract]	'
Potentially Dilutive Shares Excluded as Result of Effects Being Anti-dilutive	'
		Three and Nine Months Ended
		September 30,
		2013		2012
	Dilutive shares:
	Convertible preferred stock		73,332		73,332
	Additional stock issuable related to conversion of preferred stock		59,154		-
	Restricted share units		802,800		52,900
	Warrants		2,305,272		2,951,404
	Stock options		1,832,581		1,704,110
	Total dilutive shares		5,073,139		4,781,746

Acquisition_Tables

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2013
Acquisition [Abstract]	'
Preliminary Allocation of Purchase Price to Estimated Fair Values of Assets Acquired and Liabilities Assumed	'
	Current assets	$	925,817
	Equipment		29,579
	Acquired intangible assets		10,700,000
	Goodwill		6,337,967
	Total assets acquired		17,993,363
	Current liabilities		653,315
	Deferred tax liability		2,982,470
	Total liabilities assumed		3,635,785
	Net assets acquired	$	14,357,578
	Purchase price	$	14,475,000
	Less cash acquired		117,422
	Net cash paid	$	14,357,578
Combined Results of Operations as if Acquisition Had Occurred at Beginning of Period	'
		Nine months ended,
		30-Sep-12
		(Unaudited)
	Net Sales	$	53,924,427
	Net Loss	$	(8,898,587	)
	Net Loss per common share:
	Basic and Diluted	$	(0.74	)
	Weighted average number of shares:
	Basic and Diluted		12,068,520

Cash_and_Cash_Equivalents_and_1

Cash and Cash Equivalents and Investments (Tables)	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents and Investments [Abstract]	'
Schedule of Cash and Cash Equivalents and Investments	'
		September 30,		December 31,
		2013		2012
	Cash	$	3,939,203	$	4,909,663
	Money market mutual funds		1,454,585		36,706,994
	Cash and cash equivalents		5,393,788		41,616,657
	Investments in debt securities		21,971,000		4,228,000
	Investment in equity securities		7,941,931		-
	Total Investments		29,912,931		4,228,000
	Total cash and cash equivalents and investments	$	35,306,719	$	45,844,657
Fair Value of Cash and Cash Equivalents and Investments	'
				Fair Value Measurements, Using
		Total carrying		Quoted prices		Significant other		Significant
		value as of		in active		observable		unobservable
		September 30,		markets		inputs		inputs
		2013		(Level 1)		(Level 2)		(Level 3)
	Cash and cash equivalents	$	5,393,788	$	5,393,788	$	-	$	-
	Investments in debt securities		21,971,000		21,959,311		-		-
	Investment in equity securities		7,941,931		7,941,931		-		-
	Total Investments		29,912,931		29,901,242		-		-
	Total	$	35,306,719	$	35,295,030	$	-	$	-

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventories [Abstract]	'
Schedule of Inventories	'
		September 30,		December 31,
		2013		2012
	Finished goods	$	10,037,372	$	9,574,685
	Work in process		889,754		554,129
	Packaging materials		1,139,886		991,157
	Raw materials		3,020,573		2,550,617
	Total inventory	$	15,087,585	$	13,670,588

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity [Abstract]	'
Schedule of Warrants Outstanding	'
	Series	Number of Warrants			Exercise Price			Expiration Date
	L		6,250		$	3.12		31-Mar-14
	N		100,000		$	6.25		22-Feb-15
	O		230,900		$	5.5		22-Feb-15
	P		2,187		$	6.25		16-Feb-15
	Q		133,333		$	5.5		22-Feb-15
	R		1,832,602		$	9.9		22-Jun-16
	Total		2,305,272
Weighted Average Assumptions Used in Estimation of Fair Value of Option Awards	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Risk-free interest rate		2	%		0.9	%		1.26	%		1.12	%
	Volatility factor		67.9	%		72.2	%		69.9	%		74.4	%
	Dividend yield		0	%		0	%		0	%		0	%
	Expected option life (years)		6.25			6.25			6.25			6.25
Summary of Stock Option Activity	'
		Options			Weighted
					Average
					Exercise Price
	Outstanding - January 1, 2013		1,639,985		$	6.38
	Granted		414,230		$	12.15
	Exercised		(178,261	)	$	5.58
	Forfeited		(19,918	)	$	9.94
	Expired		(23,455	)	$	13.47
	Outstanding - September 30, 2013		1,832,581		$	7.69
	Expected to vest - September 30, 2013		1,814,255		$	7.69
	Exercisable at September 30, 2013		1,335,542		$	6.46
Allocation of Stock Option Compensation Expense	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Cost of sales	$	17,337		$	9,362		$	85,678		$	30,427
	Selling, general and administrative expenses		536,755			286,402			1,672,548			1,301,442
	Research and development		55,925			13,913			127,580			31,162
	Total stock option compensation expense	$	610,017		$	309,677		$	1,885,806		$	1,363,031
Summary of Restricted Share Unit Activity	'
		Number			Weighted
		of Shares			Average Fair Value
	Unvested January, 1, 2013		786,900		$	7.07
	Granted		82,800			13.66
	Vested		(66,900	)		9.52
	Unvested, September 30, 2013		802,800		$	9.22
Common Stock Shares Reserved for Future Issuance	'
	Convertible preferred shares (series A - B)		73,332
	Additional stock issuable related to conversion of preferred stock		59,154
	Common stock options outstanding		1,832,581
	Common stock warrants outstanding		2,305,272
	Restricted share units outstanding		802,800
	Common stock equivalents available for grant		1,436,849
	Total common stock shares reserved		6,509,988

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Schedule of Accumulated Other Comprehensive Income	'
		Foreign Currency			Unrealized Gain on		Total
		Translation			Equity Securities,
		Adjustments			Net of Taxes
	Balance at January 1, 2013	$	1,588,888		$	-	$	1,588,888
	Current period - other comprehensive income (loss)		(190,039	)		579,711		389,672
	Balance at September 30, 2013	$	1,398,849		$	579,711	$	1,978,560

Operating_Segments_Tables

Operating Segments (Tables)	9 Months Ended
	Sep. 30, 2013
Operating Segments [Abstract]	'
Schedule of Operating Segment Sales, Gross Profit, Segment Contribution and Other Related Information	'
	Three Months Ended September 30, 2013
		Advanced			Traditional			Pharmaceutical			Other			Total
		Wound Care			Wound Care			Wound Care						Company
	Net sales	$	9,090,598		$	12,989,836		$	-		$	-		$	22,080,434
	Gross profit		4,524,951			3,508,823			-			-			8,033,774
	Direct expense		(5,451,888	)		(1,367,019	)		(2,704,215	)		-			(9,523,122	)
	Segment contribution	$	(926,937	)	$	2,141,804		$	(2,704,215	)		-			(1,489,348	)
	Indirect expenses										$	(3,459,415	)		(3,459,415	)
	Net loss													$	(4,948,763	)
	Three Months Ended September 30, 2012
	Net sales	$	6,829,168		$	12,820,605		$	-		$	-		$	19,649,773
	Gross profit		3,557,759			3,350,415			-			-			6,908,174
	Direct expense		(4,466,645	)		(1,058,973	)		(1,935,919	)		-			(7,461,537	)
	Segment contribution	$	(908,886	)	$	2,291,442		$	(1,935,919	)		-			(553,363	)
	Indirect expenses										$	(2,501,643	)		(2,501,643	)
	Net loss													$	(3,055,006	)
	Nine Months Ended September 30, 2013
		Advanced			Traditional			Pharmaceutical			Other			Total
		Wound Care			Wound Care			Wound Care						Company
	Net sales	$	24,489,596		$	34,528,645		$	-		$	-		$	59,018,241
	Gross profit		12,080,637			9,331,763			-			-			21,412,400
	Direct expense		(15,883,488	)		(3,847,234	)		(8,989,976	)		-			(28,720,698	)
	Segment contribution	$	(3,802,851	)	$	5,484,529		$	(8,989,976	)		-			(7,308,298	)
	Indirect expenses										$	(11,229,917	)		(11,229,917	)
	Net loss													$	(18,538,215	)
	Nine Months Ended September 30, 2012
	Net sales	$	17,126,374		$	35,410,564		$	-		$	-		$	52,536,938
	Gross profit		8,787,986			9,194,923			-			-			17,982,909
	Direct expense		(12,695,205	)		(3,311,086	)		(4,593,012	)		-			(20,599,303	)
	Segment contribution	$	(3,907,219	)	$	5,883,837		$	(4,593,012	)		-			(2,616,394	)
	Indirect expenses										$	(5,769,562	)		(5,769,562	)
	Net loss													$	(8,385,956	)
Schedule of Net Sales by Geographic Region	'
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	United States		77	%		70	%		78	%		70	%
	Canada		13	%		22	%		13	%		21	%
	Other		10	%		8	%		9	%		9	%

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2013
Income Taxes [Abstract]	'
Income Tax Benefit and Effective Tax Rate	'
		Three Months Ended September 30,
		2013			2012
	Current tax expense	$	31,819		$	20,551
	Deferred tax (benefit) expense		(309,574	)		29,753
	Income tax (benefit) expense	$	(277,755	)	$	50,304
	Effective tax rate		5.3	%		(1.7	)%
		Nine Months Ended September 30,
		2013			2012
	Current tax (benefit) expense	$	(59,035	)	$	47,323
	Deferred tax benefit		(234,934	)		(1,799,970	)
	Income tax benefit	$	(293,969	)	$	(1,752,647	)
	Effective tax rate		1.6	%		17.3	%

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies (Narrative) (Details)	9 Months Ended
	Sep. 30, 2013
Organization and Summary of Significant Accounting Policies [Abstract]	'
Number of operating segments	3

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies (Potentially Dilutive Shares Excluded as Result of Effects Being Anti-dilutive) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	5,073,139	4,781,746	5,073,139	4,781,746
Convertible preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	73,332	73,332	73,332	73,332
Additional stock issuable related to conversion of preferred stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	59,154	'	59,154	'
Restricted share units [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	802,800	52,900	802,800	52,900
Warrants [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	2,305,272	2,951,404	2,305,272	2,951,404
Stock options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Dilutive shares	1,832,581	1,704,110	1,832,581	1,704,110

Acquisition_Preliminary_Alloca

Acquisition (Preliminary Allocation of Purchase Price to Estimated Fair Values of Assets Acquired and Liabilities Assumed) (Details) (USD $)	0 Months Ended	9 Months Ended
	Apr. 16, 2012	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
Acquisition [Abstract]	'	'	'	'
Current assets	$925,817	'	'	'
Equipment	29,579	'	'	'
Acquired intangible assets	10,700,000	'	'	'
Goodwill	6,337,967	'	13,457,693	13,457,693
Total assets acquired	17,993,363	'	'	'
Current liabilities	653,315	'	'	'
Deferred tax liability	2,982,470	'	'	'
Total liabilities assumed	3,635,785	'	'	'
Net assets acquired	14,357,578	'	'	'
Purchase price	14,475,000	'	'	'
Less cash acquired	117,422	'	'	'
Net cash paid	$14,357,578	$14,357,578	'	'

Acquisition_Combined_Results_o

Acquisition (Combined Results of Operations as if Acquisition Had Occurred at Beginning of Period) (Details) (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2013
Acquisition [Abstract]	'	'
Net Sales	$53,924,427	'
Net Loss	-8,898,587	'
Net Loss per common share - basic and diluted	($0.74)	'
Weighted average number of shares - basic and diluted	12,068,520	'
Amortization of intangible assets	'	$1,934,153

Cash_and_Cash_Equivalents_and_2

Cash and Cash Equivalents and Investments (Schedule of Cash and Cash Equivalents and Investments) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Cash and Cash Equivalents and Investments [Abstract]	'	'	'	'
Cash	$3,939,203	$4,909,663	'	'
Money market mutual funds	1,454,585	36,706,994	'	'
Cash and cash equivalents	5,393,788	41,616,657	10,895,234	17,110,350
Investments in debt securities	21,971,000	4,228,000	'	'
Investments in equity securities	7,941,931	'	'	'
Total Investments	29,912,931	4,228,000	'	'
Total cash and cash equivalents and investments	$35,306,719	$45,844,657	'	'

Cash_and_Cash_Equivalents_and_3

Cash and Cash Equivalents and Investments (Fair Value of Cash and Cash Equivalents and Investments) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	$5,393,788	'
Investments	29,912,931	'
Total cash and cash equivalents and investments	35,306,719	45,844,657
Quoted prices in active markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	5,393,788	'
Investments	29,901,242	'
Total cash and cash equivalents and investments	35,295,030	'
Significant other observable inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	'	'
Investments	'	'
Total cash and cash equivalents and investments	'	'
Significant unobservable inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	'	'
Investments	'	'
Total cash and cash equivalents and investments	'	'
Debt Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investments	21,971,000	'
Debt Securities [Member] | Quoted prices in active markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investments	21,971,000	'
Debt Securities [Member] | Significant other observable inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investments	'	'
Debt Securities [Member] | Significant unobservable inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investments	'	'
Equity Securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investments	7,941,931	'
Equity Securities [Member] | Quoted prices in active markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investments	7,941,931	'
Equity Securities [Member] | Significant other observable inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investments	'	'
Equity Securities [Member] | Significant unobservable inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investments	'	'

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventories [Abstract]	'	'
Finished goods	$10,037,372	$9,574,685
Work in process	889,754	554,129
Packaging materials	1,139,886	991,157
Raw materials	3,020,573	2,550,617
Total inventory	$15,087,585	$13,670,588

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

22-May-13

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

22-May-13

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Retiring Director [Member]

Stock options [Member]

Stock options [Member]

Stock options [Member]

Stock options [Member]

Restricted share units [Member]

Restricted share units [Member]

Restricted share units [Member]

Restricted share units [Member]

Service based options [Member]

Performance based options [Member]

2012 Plan [Member]

2012 Plan [Member]

2012 Plan [Member]

2012 Plan [Member]

Conversion Ratio Adjustments [Member]

Stock options [Member]

Restricted share units [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible preferred stock, shares outstanding

73,332

'

'

73,332

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock shares issuable for preferred stock

121,089

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,397

Additional shares issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

141,448

Proceeds from the sale of common stock, net of costs

'

$17,799,874

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares sold

743,763

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

35,000,000

'

35,000,000

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount received upon the exercise of stock purchase warrants and options

2,811,218

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of stock purchase warrants and options exercised

28,208

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock issued in connection with the vesting of restricted common stock

58,970

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of restricted common stock vested

66,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of preferred stock, shares issued

130,051

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of options exercised

1,229,992

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase shares of common stock

2,305,272

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares authorized previously

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

2,812,500

'

'

'

Number of shares of common stock authorized to be issued pursuant to the plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

4,500,000

'

'

'

Number of shares reserved for issuance under the plan

6,509,988

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,832,581

802,800

'

Shares outstanding

1,832,581

'

'

1,639,985

'

'

'

'

'

'

'

'

'

'

'

'

'

1,832,581

802,800

'

Shares available for grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,436,849

'

'

'

'

Contractual option life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

Granted

414,230

'

'

'

'

'

'

'

'

'

'

'

'

288,630

125,600

'

'

'

'

'

Shares of common stock issued upon the exercise of stock purchase warrants and options

550,292

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average fair value per share of options granted

$8.29

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost

'

'

'

'

'

'

'

'

'

5,449,413

'

5,449,413

'

1,960,427

320,857

'

'

'

'

'

Remaining weighted average vesting period

'

'

'

'

'

'

'

'

'

'

'

'2 years 5 months 5 days

'

'1 year 10 months 6 days

'3 months

'

'

'

'

'

Shares withheld in satisfaction of employee tax withholding obligations

'

'

'

'

'

'

'

'

'

'

'

7,930

'

'

'

'

'

'

'

'

Fair value of shares withheld in satisfaction of employee tax withholding obligations

'

'

'

'

'

'

'

'

'

'

'

76,446

'

'

'

'

'

'

'

'

Shares issued to retiring director

4,450

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Extension of the period of time to exercise vested stock options

'

'

'

'

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of time to exercise vested stock options

'

'

'

'

'90 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option compensation expense

'

'

'

'

$337,422

$610,017

$309,677

$1,885,806

$1,363,031

$745,067

$109,289

$1,937,993

$307,257

'

'

'

'

'

'

'

Stockholders_Equity_Schedule_o

Stockholders' Equity (Schedule of Warrants Outstanding) (Details)	9 Months Ended
	Sep. 30, 2013
Class of Warrant or Right [Line Items]	'
Number of Warrants	2,305,272
Warrants exercised	624,882
Warrants exercised, shares issued	421,465
J [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants exercised	200,893
K [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants exercised	367,814
L [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	6,250
Exercise Price	3.12
Expiration Date	31-Mar-14
N [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	100,000
Exercise Price	6.25
Expiration Date	22-Feb-15
O [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	230,900
Exercise Price	5.5
Expiration Date	22-Feb-15
Warrants exercised	53,667
P [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	2,187
Exercise Price	6.25
Expiration Date	16-Feb-15
Warrants exercised	2,508
Q [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	133,333
Exercise Price	5.5
Expiration Date	22-Feb-15
R [Member]	'
Class of Warrant or Right [Line Items]	'
Number of Warrants	1,832,602
Exercise Price	9.9
Expiration Date	22-Jun-16

Stockholders_Equity_Weighted_A

Stockholders' Equity (Weighted Average Assumptions Used in Estimation of Fair Value of Option Awards) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stockholders' Equity [Abstract]	'	'	'	'
Risk free interest rate	2.00%	0.90%	1.26%	1.12%
Volatility factor	67.90%	72.20%	69.90%	74.40%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected option life (years)	'6 years 3 months	'6 years 3 months	'6 years 3 months	'6 years 3 months
Forfeiture rate	1.00%	1.00%	1.00%	1.00%

Stockholders_Equity_Summary_of

Stockholders' Equity (Summary of Stock Option Activity) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Number of Shares	'
Outstanding - beginning balance	1,639,985
Granted	414,230
Exercised	-178,261
Forfeited	-19,918
Expired	-23,455
Outstanding - ending balance	1,832,581
Expected to vest	1,814,255
Exercisable	1,335,542
Weighted Average Exercise Price Per Share	'
Outstanding - beginning balance	$6.38
Granted	$12.15
Exercised	$5.58
Forfeited	$9.94
Expired	$13.47
Outstanding - ending balance	$7.69
Expected to vest	$7.69
Exercisable	$6.46

Stockholders_Equity_Allocation

Stockholders' Equity (Allocation of Stock Option Compensation Expense) (Details) (Stock options [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock option compensation expense	$610,017	$309,677	$1,885,806	$1,363,031
Cost of sales [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock option compensation expense	17,337	9,362	85,678	30,427
Selling, general and administrative expenses [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock option compensation expense	536,755	286,402	1,672,548	1,301,442
Research and development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock option compensation expense	$55,925	$13,913	$127,580	$31,162

Stockholders_Equity_Summary_of1

Stockholders' Equity (Summary of Restricted Share Unit Activity) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Number of Shares	'
Unvested beginning balance	786,900
Granted	82,800
Vested	-66,900
Unvested ending balance	802,800
Weighted Average Fair Value	'
Unvested beginning balance	$7.07
Granted	$13.66
Vested	$9.52
Unvested ending balance	$9.22

Stockholders_Equity_Common_Sto

Stockholders' Equity (Common Stock Shares Reserved for Future Issuance) (Details)	Sep. 30, 2013
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	6,509,988
Convertible preferred shares (series A - B) [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	73,332
Additional stock issuable related to conversion of preferred stock [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	59,154
Common stock options outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	1,832,581
Common stock warrants outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	2,305,272
Restricted share units outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	802,800
Common stock equivalents available for grant [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	1,436,849

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	'	'	$1,588,888	'
Current period - other comprehensive income (loss)	608,772	156,283	389,672	149,113
Ending balance	1,978,560	'	1,978,560	'
Foreign Currency Translation Adjustments [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	'	'	1,588,888	'
Current period - other comprehensive income (loss)	'	'	-190,039	'
Ending balance	1,398,849	'	1,398,849	'
Unrealized Gain on Equity Securities, Net of Taxes [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Beginning balance	'	'	'	'
Current period - other comprehensive income (loss)	'	'	579,711	'
Ending balance	$579,711	'	$579,711	'

Operating_Segments_Narrative_D

Operating Segments (Narrative) (Details) (Net sales [Member], Customer [Member])	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Net sales [Member] | Customer [Member]	'	'
Concentration Risk [Line Items]	'	'
Concentration percentage	12.00%	20.00%

Operating_Segments_Schedule_of

Operating Segments (Schedule of Operating Segment Sales, Gross Profit, Segment Contribution and Other Related Information) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$22,080,434	$19,649,773	$59,018,241	$52,536,938
Gross profit	8,033,774	6,908,174	21,412,400	17,982,909
Direct expense	-9,523,122	-7,461,537	-28,720,698	-20,599,303
Segment contribution	-1,489,348	-553,363	-7,308,298	-2,616,394
Indirect expenses	-3,459,415	-2,501,643	-11,229,917	-5,769,562
Net Loss	-4,948,763	-3,055,006	-18,538,215	-8,385,956
Advanced Wound Care [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	9,090,598	6,829,168	24,489,596	17,126,374
Gross profit	4,524,951	3,557,759	12,080,637	8,787,986
Direct expense	-5,451,888	-4,466,645	-15,883,488	-12,695,205
Segment contribution	-926,937	-908,886	-3,802,851	-3,907,219
Traditional Wound Care [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	12,989,836	12,820,605	34,528,645	35,410,564
Gross profit	3,508,823	3,350,415	9,331,763	9,194,923
Direct expense	-1,367,019	-1,058,973	-3,847,234	-3,311,086
Segment contribution	2,141,804	2,291,442	5,484,529	5,883,837
Pharmaceutical Wound Care [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	'	'	'	'
Gross profit	'	'	'	'
Direct expense	-2,704,215	-1,935,919	-8,989,976	-4,593,012
Segment contribution	-2,704,215	-1,935,919	-8,989,976	-4,593,012
Other [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	'	'	'	'
Gross profit	'	'	'	'
Direct expense	'	'	'	'
Segment contribution	'	'	'	'
Indirect expenses	($3,459,415)	($2,501,643)	($11,229,917)	($5,769,562)

Operating_Segments_Schedule_of1

Operating Segments (Schedule of Net Sales by Geographic Region) (Details) (Net sales [Member])	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Unites States [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Concentration percentage	77.00%	70.00%	78.00%	70.00%
Canada [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Concentration percentage	13.00%	22.00%	13.00%	21.00%
Other [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Concentration percentage	10.00%	8.00%	9.00%	9.00%

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Taxes [Abstract]	'	'	'	'
Current tax benefit	$31,819	$20,551	($59,035)	$47,323
Deferred tax expense	-309,574	29,753	-234,934	-1,799,970
Income tax expense	-277,755	50,304	-293,969	-1,752,647
Effective tax rate	5.30%	-1.70%	1.60%	17.30%
Change in valuation allowance	'	'	($1,887,383)	'

Investment_in_Comvita_Details

Investment in Comvita (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Investment in Comvita [Abstract]	'
Shares of common stock	2,272,277
Cost of shares acquired	$7,000,000
Ownership percentage	7.30%
Quoted market value	7,941,931
Unrealized gain on equity securities	941,931
Unrealized gain on equity securities, taxes	$362,220

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
Cash paid for agreement	$200,000
Refundable amount	100,000
Identifiable intangible asset	100,000
Term of agreement	'5 years
Deposit	100,000
Maximum milestone payments	$1,000,000